Clinical and Translational Oncology

, Volume 11, Issue 7, pp 428–436

Clinical-molecular factors predicting response and survival for tyrosine-kinase inhibitors

  • Mariano Provencio
  • Rosario García-Campelo
  • Dolores Isla
  • Javier de Castro
Educational Series Molecular Targets in Oncology

DOI: 10.1007/s12094-009-0381-3

Cite this article as:
Provencio, M., García-Campelo, R., Isla, D. et al. Clin Transl Oncol (2009) 11: 428. doi:10.1007/s12094-009-0381-3
  • 35 Views

Abstract

The development of drugs with special mechanisms of action, such as tyrosine kinase inhibitors (TKIs), means that new clinical-molecular questions are being examined and this will help us to better select from the treatments available. In this study we review questions of survival and response to TKIs, attempting to distinguish prediction-and prognosis-related factors, at both the clinical and molecular levels. The evidence available today allows us to affirm that the benefits of TKI treatment occur regardless of the patient’s status as a smoker, his/her gender or histological sub-type. Interestingly, in a subset analysis of ever-smokers, men with squamous cell histology derived a statistically significant survival benefit from erlotinib, a population that was previously thought not to benefit. The question of who should receive TKIs is still not completely resolved. Therefore, there should be an international effort to achieve a prognostic index, as has been done for lymphomas, that combines molecular and clinical factors. Such an index would classify patients into several sub-groups, defining the likelihood of non-response to TKIs.

Keywords

Tyrosine kinase inhibitorLung cancerEGFRResistanceSurvival

Copyright information

© Feseo 2009

Authors and Affiliations

  • Mariano Provencio
    • 1
  • Rosario García-Campelo
    • 2
  • Dolores Isla
    • 3
  • Javier de Castro
    • 4
  1. 1.Medical Oncology DepartmentHospital Universitario Puerta de HierroMajadahonda, MadridSpain
  2. 2.Medical Oncology DepartmentHospital Juan CanalejoLa CoruñaSpain
  3. 3.Medical Oncology DepartmentHospital Lozano BlesaZaragozaSpain
  4. 4.Medical Oncology DepartmentHospital La PazMadridSpain